Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access for KHK2455

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04321694
Expanded Access Status : No longer available
First Posted : March 25, 2020
Last Update Posted : August 10, 2021
Sponsor:
Collaborator:
University of New Mexico Cancer Center
Information provided by (Responsible Party):
Kyowa Kirin, Inc.

Brief Summary:
This is an expanded access program for eligible participants. This program is designed to provide access to KHK2455 in combination with Mogamulizumab prior to the approval by the local regulatory agency. A medical doctor must decide whether the potential benefit outweighs the risk of receiving this investigational therapy based on the individual patients medical history and eligibility criteria.

Condition or disease Intervention/treatment
Glioblastoma Multiforme Drug: KHK2455

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Individual Patients
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: Expanded Access for KHK2455



Intervention Details:
  • Drug: KHK2455
    Other Name: Mogamulizumab

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Criteria

Inclusion Criteria:

-

Exclusion Criteria:

-


No Contacts or Locations Provided
Layout table for additonal information
Responsible Party: Kyowa Kirin, Inc.
ClinicalTrials.gov Identifier: NCT04321694    
Other Study ID Numbers: Expanded Access for KHK2455
First Posted: March 25, 2020    Key Record Dates
Last Update Posted: August 10, 2021
Last Verified: March 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioblastoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Mogamulizumab
Antineoplastic Agents